Site icon Hot Paths

PTC’s utreloxastat fails Phase 2 clinical study for ALS (NASDAQ:PTCT)

Press Room
ALS or Written on wooden blocks, Amyotrophic lateral sclerosis, a rare nervous system disease affecting the motor nerves in the cortex and brainstem and spinal cord, loss of muscle control

Andrzej Rostek

  • PTC Therapeutics (NASDAQ:PTCT) said a Phase 2 placebo-controlled study of its ALS drug candidate utreloxastat failed to meet its primary and secondary efficacy endpoints.
  • The biotech company said the drug failed to demonstrate statistical significance in the slowing of disease
Exit mobile version